Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.43 |
| ▸ | THRA | P10827 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.39 |
| ▸ | EYA3 | Q99504 | 2/20 | 0.39 |
| ▸ | PLK1 | P53350 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | ITK | Q08881 | 1/20 | 0.37 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29958615 | 0.99 | CA2 (0.42) | CA2NR1I3THRATHRBCYP2C19 | |
| SCHEMBL1252616 | 0.82 | CYP2C19 (0.43) | THRBCYP2C19EYA3PLK1MEN1 | |
| SCHEMBL725375 | 0.81 | HCRTR1 (0.41) | CYP2C19KMT2AEGFRITKHCRTR1 | |
| Hydrochloric Acid SCHEMBL4794398 | 0.80 | HCRTR1 (0.41) | CYP2C19KMT2AEGFRITKHCRTR1 | |
| SCHEMBL1253615 | 0.80 | CYP2C9 (0.40) | THRATHRBCYP2C19EYA3MEN1 | |
| SCHEMBL725450 | 0.76 | CA2 (0.37) | CA2 | |
| SCHEMBL725451 | 0.76 | CA2 (0.37) | CA2 | |
| SCHEMBL21963757 | 0.75 | EGFR (0.33) | MEN1KMT2AEGFRITK | |
| Hydrochloric Acid SCHEMBL1251727 | 0.75 | — | — | |
| Hydrochloric Acid SCHEMBL1251730 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115151541-B | Novel compounds and uses thereof | 德彪药业国际股份公司 | 2024-06-25 | — | — | CN | claimed |
| CN-115151541-A | Novel compound and use thereof | 德彪药业国际股份公司 | 2022-10-04 | — | — | CN | claimed |
| CN-113272302-B | Antibiotic compound, method for producing same, pharmaceutical composition containing same, and use thereof | 德彪药业国际股份公司 | 2024-08-13 | — | — | CN | disclosed |
| CN-115151541-B | Novel compounds and uses thereof | 德彪药业国际股份公司 | 2024-06-25 | — | — | CN | disclosed |
| EP-4359079-A1 | NOVEL COMPOUNDS AND THEIR USE | Debiopharm International S.A. (CH) | 2024-05-01 | — | — | EP | disclosed |
| CN-117881679-A | Novel compounds and uses thereof | 德彪药业国际股份公司 | 2024-04-12 | — | — | CN | disclosed |
| US-20230159519-A1 | NOVEL COMPOUNDS AND THEIR USE | DEBIOPHARM INTERNATIONAL S.A. (CH) | 2023-05-25 | — | — | US | disclosed |
| US-20230159519-A1 | NOVEL COMPOUNDS AND THEIR USE | DEBIOPHARM INTERNATIONAL S.A. (CH) | 2023-05-25 | — | — | US | disclosed |
| US-20230035837-A1 | ANTIBIOTIC COMPOUNDS, METHODS OF MANUFACTURING THE SAME, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND USES THEREOF | DEBIOPHARM INTERNATIONAL S.A. (CH) | 2023-02-02 | — | — | US | disclosed |
| WO-2022268890-A1 | NOVEL COMPOUNDS AND THEIR USE | DEBIOPHARM INTERNATIONAL S.A. (CH) | 2022-12-29 | — | — | WO | disclosed |
| WO-2022268890-A1 | NOVEL COMPOUNDS AND THEIR USE | DEBIOPHARM INTERNATIONAL S.A. (CH) | 2022-12-29 | — | — | WO | disclosed |
| EP-4077324-A1 | NOVEL COMPOUNDS AND THEIR USE | Debiopharm International SA (CH) | 2022-10-26 | — | — | EP | disclosed |
| CN-115151541-A | Novel compound and use thereof | 德彪药业国际股份公司 | 2022-10-04 | — | — | CN | disclosed |
| CN-113272302-A | Antibiotic compounds, process for their manufacture, pharmaceutical compositions containing them and their use | 德彪药业国际股份公司 | 2021-08-17 | — | — | CN | disclosed |
| WO-2021123372-A1 | NOVEL COMPOUNDS AND THEIR USE | DEBIOPHARM INTERNATIONAL S.A. (CH) | 2021-06-24 | — | — | WO | disclosed |
| WO-2020099341-A1 | ANTIBIOTIC COMPOUNDS, METHODS OF MANUFACTURING THE SAME, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND USES THEREOF | DEBIOPHARM INTERNATIONAL S.A. (CH) | 2020-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159519-A1 | NOVEL COMPOUNDS AND THEIR USE | LSS, PGLS, LDHB | CA2 2594/4885NR1I3 1801/4885THRA 3863/4885 |
| US-20230035837-A1 | ANTIBIOTIC COMPOUNDS, METHODS OF MANUFACTURING THE SAME, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND USES THEREOF | GMPS, GNE, GANC | CA2 4674/4885NR1I3 2836/4885THRA 4638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.